An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Last updated: October 23, 2024
Sponsor: Bayer
Overall Status: Completed

Phase

N/A

Condition

Allergies & Asthma

Prostate Cancer

Allergy

Treatment

Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel

Clinical Study ID

NCT06498921
22743
  • Ages > 18
  • Male

Study Summary

This is an observational study in which only observations from routine clinical practices will be made. Participants will not receive any advice on treatment or any changes to healthcare as a part of the study.

In this study, medical records data of Belgian men with metastatic hormone sensitive prostate cancer (mHSPC) who had received or are receiving treatment with darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel will be studied.

mHSPC is a cancer of the prostate gland, a male reproductive gland found below the bladder. Metastatic means that the cancer has spread to other parts of the body. Hormone-sensitive means it can be treated with hormone-therapy such as androgen deprivation therapy (ADT).

ADT lowers the level of androgens, male hormones, and slows down the growth of cancer cells. However, in some cases, ADT alone is not sufficient for the treatment of mHSPC and doctors recommend a combination of treatments.

The study drug darolutamide, in combination with ADT and docetaxel is an approved treatment for mHSPC. Darolutamide aims to work by blocking the androgens signals to slow the growth of the cancer cells. Docetaxel is a medicine used to treat different types of cancer and works by stopping the growth and spread of cancer cells.

The main purpose of this study is to learn more about the real-world use of darolutamide in combination with ADT and docetaxel in Belgian men with mHSPC.

To do this, researchers will study the following information about participants who are already prescribed this combination treatment by their treating doctors in real-word condition:

  • Participants' cancer characteristics before starting the treatment, and

  • Participants' treatment history The data will be collected between July 2024 to September 2024, from eligible participants' medical records.

Study doctors will only look at the medical records of adult men with mHSPC in Belgium.

In this study, only available data from routine care will be collected. No visits or tests are required as part of this study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients diagnosed with mHSPC

  • Patients treated with darolutamide (Nubeqa, BAY1841788) in combination with ADT anddocetaxel according to local reimbursement

  • Initiation of treatment with darolutamide (Nubeqa, BAY1841788) in this indicationbetween the index date (should be before 15MAR2024) and start of data collection.

Exclusion

Exclusion Criteria:

  • Participation in an investigational program with interventions outside of routineclinical practice

  • Contraindications according to the local reimbursement

Study Design

Total Participants: 106
Treatment Group(s): 1
Primary Treatment: Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel
Phase:
Study Start date:
July 15, 2024
Estimated Completion Date:
September 15, 2024

Connect with a study center

  • Many locations

    Multiple Locations,
    Belgium

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.